塞来昔布在中国治疗骨关节炎的成本效果研究

发布时间：2018-02-11 10:15

本文关键词： 骨关节炎塞来昔布双氯芬酸质子泵抑制剂成本效果药物经济学　出处：《中国药房》2017年05期 　论文类型：期刊论文

【摘要】：目的:评估塞来昔布在中国治疗骨关节炎(OA)的成本效果。方法:采用英国国家卫生与临床优化研究所开发的一种OA成本-效果分析模型结构,对照药包括塞来昔布和双氯芬酸+质子泵抑制剂(PPIs);不良事件的相对风险来自CONDOR试验。以质量调整生命年(QALY)计量有效性;每年以折现率4.76%折减成本和QALY。结果:塞来昔布的成本为$3 591,QALY为8.826年;双氯芬酸+PPIS的成本为$3 674,QALY为8.830年。塞来昔布相对于双氯芬酸+PPIs的增量成本和增量QALY分别为$-83和-0.004QALY。双氯芬酸+PPIS相对于塞来昔布的增量成本效果比(ICER)为$23 258/QALY。单因素敏感度分析和概率敏感度分析结果显示,药物成本是ICER的主要驱动因素,且两种治疗方案的结果相似。结论:塞来昔布是一种成本低于双氯芬酸+PPIs的替代药物。两种用药方案之间的QALY差异非常小,因此塞来昔布可能是OA患者更具成本效果优势的选择。
[Abstract]:Objective: to evaluate the cost-effectiveness of celecoxib in the treatment of osteoarthritis in China. Methods: an OA cost-effectiveness analysis model was developed by the National Institute of Health and Clinical Optimization. Control drugs included celecoxib and diclofenac proton pump inhibitor PPIsa; the relative risk of adverse events came from the CONDOR trial. Results: the cost of celecoxib was 3.591g QALY 8.826 years. The cost of diclofenac PPIS is 8.830 years, the incremental cost and increment QALY of celecoxib relative to diclofenac PPIs are -83 and -0.004QALYY. the incremental cost effect of diclofenac PPIS relative to celecoxib is 23.258% QALY. Factor sensitivity analysis and probability sensitivity analysis showed that, Drug cost is the main driving factor of ICER, and the results of the two treatments are similar. Conclusion: celecoxib is an alternative drug with lower cost than diclofenac PPIs. The difference of QALY between the two regimens is very small. Therefore, celecoxib may be a more cost effective choice for OA patients.
【作者单位】：亦熙有限公司;辉瑞投资有限公司(北京分公司);密歇根大学;
【基金】：辉瑞投资有限公司资助课题
【分类号】：R684.3

【参考文献】